Cogent Biosciences (COGT) Cash from Financing Activities (2017 - 2026)

Cogent Biosciences (COGT) has reported Cash from Financing Activities for 10 consecutive years, with $52.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 110.4% year-over-year to $52.5 million; the TTM figure through Mar 2026 stood at $905.8 million (up 3471.2% YoY), while the FY2025 annual figure was $878.2 million, up 309.53% from the prior year.
• Cash from Financing Activities declined to $52.5 million in Q1 2026 per COGT's latest filing, from $588.7 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $588.7 million in Q4 2025 and bottomed at -$256000.0 in Q2 2024.
• Historically, Cash from Financing Activities has averaged $92.0 million across 5 years, with a median of $13.0 million in 2023.
• Annual changes were most pronounced in 2024 — Cash from Financing Activities plunged 100.16% — and 2025, when it surged 2264011.54%.
• Cogent Biosciences' Cash from Financing Activities stood at $315000.0 in 2022, then soared by 217.46% to $1.0 million in 2023, then slumped by 97.4% to $26000.0 in 2024, then soared by 2264011.54% to $588.7 million in 2025, then slumped by 91.08% to $52.5 million in 2026.
• Business Quant data shows COGT's Cash from Financing Activities at $52.5 million in Q1 2026, $588.7 million in Q4 2025, and $217.4 million in Q3 2025.